<DOC>
	<DOCNO>NCT00002628</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy use kill tumor cell , allow high dos chemotherapy use . PURPOSE : Phase I/II trial study effectiveness paclitaxel add regimen high-dose chemotherapy cyclophosphamide carboplatin follow peripheral stem cell transplantation treat woman metastatic breast cancer .</brief_summary>
	<brief_title>Addition Paclitaxel High-Dose Combination Chemotherapy Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Estimate maximum tolerate dose paclitaxel combination high-dose carboplatin/cyclophosphamide follow autologous peripheral blood stem cell support woman stage IV breast cancer . II . Assess nonhematologic toxic effect associate combination . III . Assess response rate , duration response , survival chemotherapy-sensitive woman metastatic breast cancer treat regimen . OUTLINE : This dose-finding study . All patient undergo collection peripheral blood stem cell ( PBSC ) granulocyte colony-stimulating factor ( G-CSF ) mobilization prior high-dose chemotherapy . Cohorts 3-5 patient treat successively high dose level paclitaxel maximum tolerate dose ( MTD ) find . Paclitaxel give single 24-hour infusion , follow fixed dos high-dose cyclophosphamide 2 day , carboplatin 4 day . Three day later , patient receive PBSC G-CSF hematopoietic reconstitution . Additional patient enter MTD . Patients follow every 3 month 1 year , every 4 month 1 year , every 4-6 month thereafter . PROJECTED ACCRUAL : 50 patient accrue . The study expect take 18 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically diagnose , stage IV adenocarcinoma breast Previously untreated prior adjuvant chemotherapy CR PR follow 35 course induction chemotherapy current diagnosis one following : Cyclophosphamide/doxorubicin Cyclophosphamide/methotrexate/fluorouracil Cyclophosphamide/mitoxantrone No active CNS metastasis CT MRI Hormone receptor status : Any status PATIENT CHARACTERISTICS : Age : 18 65 Sex : Women Menopausal status : Pre postmenopausal Performance status : ECOG 02 Hematopoietic : WBC great 3,000 Platelets great 100,000 Hepatic : Bilirubin great 2.0 mg/dL Renal : Creatinine clearance great 60 mL/min Cardiovascular : Left ventricular ejection fraction great 50 % MUGA echocardiogram No abnormal cardiac conduction EKG , i.e . : No second thirddegree heart block No bundlebranch block No arrhythmia except : Supraventricular sinus tachycardia Occasional premature atrial ventricular contraction Pulmonary : DLCO great 60 % predict Other : No preexist peripheral neuropathy No HIV antibody No history second malignancy within 5 year except : Nonmelanomatous skin cancer Cervical carcinoma situ No pregnant nursing woman PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Hematologically recover prior chemotherapy Endocrine therapy : Failure 1 prior hormonal regimen require ERpositive disease ( great 10 femtomoles ) unless visceral metastatic crisis require immediate chemotherapy Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2000</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>